290 related articles for article (PubMed ID: 17395657)
1. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
5. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.
Ries M; Clarke JT; Whybra C; Mehta A; Loveday KS; Brady RO; Beck M; Schiffmann R
J Clin Pharmacol; 2007 Oct; 47(10):1222-30. PubMed ID: 17698592
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
[TBL] [Abstract][Full Text] [Related]
9. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
14. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
15. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.
Schiffmann R; Martin RA; Reimschisel T; Johnson K; Castaneda V; Lien YH; Pastores GM; Kampmann C; Ries M; Clarke JT
J Pediatr; 2010 May; 156(5):832-7, 837.e1. PubMed ID: 20097359
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.
Clarke JT; West ML; Bultas J; Schiffmann R
Genet Med; 2007 Aug; 9(8):504-9. PubMed ID: 17700388
[TBL] [Abstract][Full Text] [Related]
20. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]